

## Lyme - Borreliose und Ko – Infektionen in der Gastroenterologie Lyme disease and Coinfections in Gastroenterology

### Immunosystem

Schuerer-Maly CC (1995), Campbell AK (2010), Stoll ML (2014), Costello ME (2014), Salvioli B, (2015), Perlmutter D (2015)

### Viruses

Goellner MH (1988), Ruane PJ (1989), Dauzan YR (1990), Chiodini RJ (1993), Prantera C (1994), Fried MD (1996, 1999, 2x2002, 2004), Zaidi SA (2002), Sherr VT (2006), Borody TJ (2007), Chamberlin W et al. (2007), Clancy R et al. (2007), Selby W et al. (2007), Stein M. (2009), Schweig S (2014)

### Bacteria

Dejea ChM (2018)

### Mycoses, fungi

Munoz P (1996, 2005), McFarland LV (2002), Cordell B (2013)

**Steere AC**, Bartenhagen NH, Craft JE, et al. (1983) The early clinical manifestations of Lyme disease. Ann Intern Med 99, 76-82

Goellner MH, Agger WA, Burgess JH, Duray PH. (1988) Hepatitis due to recurrent Lyme disease. Ann Intern Med 108, 707-708.

Duray PH, Steere AC. (1988) Clinical pathologic correlations of Lyme disease by stage. Ann NY Acad Sci 539, 65-79.

Steere AC. (1989) Lyme disease. N Engl J Med 321, 586-596

Ruane PJ, Nakata MM, Reinhardt JF, George WL (1989) Spirochete-like organisms in the human gastrointestinal tract. Rev Infect Dis 11, 184-186.

Dauzan YR, Merlio JP, Grelier P, Ip Kan Fong H, Dachary D, Goussot JF, de Mascarel A. (1990) Colorectal spirochetosis. Ann Pathol 10, 258-261

Dupont HT, Raoult D, Brouqui P et al (1992) Epidemiologic features and clinical presentations of acute Q fever in hospitalized patients: 323 French cases, Am J Med 93, 427-34.

Chiodini RJ, Hermon-Taylor J (1993) The thermal resistance of Mycobacterium paratuberculosis in raw milk under conditions simulating pasteurisation. Journal of Veterinary Diagnostic Investigation 5, 629-631

Prantera C, Kohn A et al. (1994) Antimycobacterial therapy in **Crohn's disease**: results of a controlled, double-blind trial with a **multiple antibiotic regimen**. Am J Gastroenterol 89(4), 513-8  
<http://www.ncbi.nlm.nih.gov/pubmed/8147352>

**„This study suggests that the treatment regimen with rifampicin, ethambutol, clofazimine, and dapsone is effective in relief of symptoms and maintenance of remission in some Crohn's disease patients.“**

Schuerer-Maly CC, Eckman L, Kagnoff MF, Falco MT, Maly FE. (1995) Colonic epithelial cell lines as a source of interleukin-8: Stimulation by inflammatory cytokines and bacterial lipopolysaccharide. Immunology 81, 85-91.

Fried MD, Duray P, Pietrucha D (1996) Gastrointestinal pathology in children with Lyme disease. Journal of Spirochetal and Tick-borne Diseases 3, 101-104.

Munoz P, Bouza E, Cuenca-Estrella M et al (1998) Species identification and **virulence attributes** of *Saccharomyces boulardii* (nom. inval.). J Clin Microbiol 36, 2613 - 7. [Abstract / FREE Full Text](#)

Fried MD, Abel M, Pietrucha D, Yen-Hong K, Ball A (1999) The spectrum of gastrointestinal manifestations in children and adolescents with Lyme disease. J Spirochetal and Tick-Borne Diseases, 6, 89-93

Kimmig P, Hassler D, Braun R (2000) Zecken, Kleiner Stich mit bösen Folgen, Verlag Ehrenwirth Ratgeber, ISBN 3-431-04018-7

H. Gerhardt H, F. Seifert F, P. Buvari P et al. (2001) Therapy of active Crohn disease with *Boswellia serrata* extract H 15. Z Gastroenterol. 39(1) 11–17, [ISSN 0044-2771](#), [doi:10.1055/s-2001-10708](#), [PMID 11215357](#)

Zaidi SA, Singer C. (2002) Gastrointestinal and hepatic manifestations of tickborne diseases in the United States. Clin Infect Dis. 34(9), 1206-12. Epub 2002 Apr 2. Review.

Fried, MD, Pietrucha D et al. (2002) *Borrelia burgdorferi* persists in the Gastrointestinal tract of Children and Adolescents with Lyme Disease. Journal of Spirochetal and Tick- Borne Diseases. Vol. 9, No. 1, 11-15.

Fried MD, Schairer J, Madigan G, Ball A. (2002) **Bartonella henselae** is associated with heartburn, abdominal pain, skin rash, mesenteric adenitis, gastritis and duodenitis. J Pediatr. Gastroenterol. Nutr. 35, 3 Abstract 158

McFarland LV (2002) Seven cases of **fungemia with *Saccharomyces boulardii*** in critically ill patients . Intensive Care Med 28, 797 - 801 . [CrossRefMedlineWeb of Science](#)

Rösch M et al. (2002) Kostenerfassung bei chronisch entzündlichen Darmerkrankungen durch direkte Patientenbefragung mit einem Kostenwochenbuch. Zeitschrift für Gastroenterologie 40, 217-228

Fried MD, Adelson ME, Mordechai E (2004) Simultaneous Gastrointestinal Infections in Children and Adolescents, Practical Gastroenterology, 87-80.

Stoll M, Schreiber S (2004) Morbus Crohn: Zweites krankheitsassoziiertes Gen entdeckt. In: [Biologie in unserer Zeit](#). 34(4), 208–209, [ISSN 0045-205X](#)

Klemann W (2005) Gastrointestinale Manifestationen der Borreliose und zu beachtende Co-Infektionen – eine Literaturübersicht. Referat auf der Herbsttagung der Borreliose-Gesellschaft. <http://www.dr-w-klemann.de/htmldocs/neuigkeiten-gastrointestinale-manifestationen-der-borreliose.htm>

Muñoz P, Bouza E, Cuenca-Estrella M (2005) ***Saccharomyces cerevisiae* fungemia**: an emerging infectious disease. Clin Infect Dis 40, 1625 - 34. [Abstract / FREE Full Text](#)

Sherr VT (2006) Bell's Palsy of the Gut and other Manifestations of Lyme and Associated Diseases. Practical Gastroenterology. <http://thehumansideoflyme.net/viewarticle.php?aid=62>

Fellermann K, Stange DE, Schaeffeler E et al. (2006) A chromosome 8 gene cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn's disease of the colon. In: Am. J. Hum. Genet. 79 439–448.

Stark R et al. (2006) Costs of inflammatory bowel disease in Germany based on a cost diary. Pharmacoeconomics 24,797-814

FDA: FDA approves remicade for children with Crohn's disease. FDA News, 19 May 2006 [http://www.msdd.com/fileadmin/files/gebrauchsinformationen/GI\\_Remicade\\_100mg\\_Pulver.pdf](http://www.msdd.com/fileadmin/files/gebrauchsinformationen/GI_Remicade_100mg_Pulver.pdf)

Borody TJ et al. (2007) **Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars**. Digestive and Liver Disease 39, 438-444

«**METHODS: Patients received rifabutin (up to 600 mg/day), clofazimine (up to 100 mg/day) and clarithromycin (up to 1 g/day) - anti-Mycobacterium avium ss paratuberculosis therapy - for 6 months to 9 years. Ramp-up dosing was used. Colonoscopies and histological analyses monitored progress.**»

Chamberlin W et al. (2007) **Successful treatment of a Crohn's Disease patient infected with bacteremic Mycobacterium paratuberculosis.** American Journal of Gastroenterology 102, 689-691  
« **The patient started treatment consisting of split doses of clarithromycin 1,000 mg daily, rifabutin 300–450 mg daily, and levofloxacin 500 mg daily** ».

Clancy R et al. (2007) Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF- $\alpha$  secretion. Digestive and Liver Disease 39, 445-451

Selby W et al. (2007) **Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease.** Gastroenterology 132, 2313-2319  
<http://www.ncbi.nlm.nih.gov/pubmed/17570206>  
« **Using combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for up to 2 years, we did not find evidence of a sustained benefit. This finding does not support a significant role for Mycobacterium avium subspecies paratuberculosis in the pathogenesis of Crohn's disease in the majority of patients. Short-term improvement was seen when this combination was added to corticosteroids, most likely because of nonspecific antibacterial effects** ».

Hoffmann JC et al. (2008) Diagnostik und Therapie des Morbus Crohn. Zeitschrift für Gastroenterologie 46, 1094–1146

Hassler D, Braun R (2009) **Antibiose statt Skalpell: Neue Erkenntnisse zum Morbus Crohn.** Deutsche Medizinische Wochenschrift 134, 10-11  
[https://www.researchgate.net/publication/245681000\\_Antibiose\\_statt\\_Skalpell\\_Neue\\_Erkenntnisse\\_zum\\_Morbus\\_Crohn](https://www.researchgate.net/publication/245681000_Antibiose_statt_Skalpell_Neue_Erkenntnisse_zum_Morbus_Crohn)

Stein M. (2009) **Morbus Crohn durch Mykobakterien Ein Verdacht wird zur Gewissheit.** EU.L.E.N-SPIEGEL • Nr. 2 / 2009 • © EU.L.E. e.V. • www.das-eule.de  
[http://www.euleev.de/images/Beitraege/Morbus\\_Crohn.pdf](http://www.euleev.de/images/Beitraege/Morbus_Crohn.pdf)

Galland L (2010) **Diet and inflammation.** Nutr Clin Pract. 25(6), 634-40.  
doi:10.1177/0884533610385703. <https://www.ncbi.nlm.nih.gov/pubmed/21139128>

Campbell AK, Matthews SB, Vassel N, Cox CD, Naseem R, Chaichi J, Holland IB, Green J, Wann KT (2010) **Bacterial metabolic 'toxins':** a new mechanism for lactose and food intolerance, and irritable bowel syndrome. Toxicology. 278(3), 268-76. doi: 10.1016/j.tox.2010.09.001. Epub 2010 Sep 18.  
<http://www.ncbi.nlm.nih.gov/pubmed/20851732>

Scher J, Abramson S. (2011) **The microbiome and rheumatoid arthritis.** Nat Rev Rheumatol. Author manuscript; available in PMC 2012 Feb 8. Published in final edited form as: Nat Rev Rheumatol. 7(10), 569–578. doi:10.1038/nrrheum.2011.121  
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275101/>

Holtmeier W, Zeuzem S, Preiß J et al. (2011) **Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy.** Inflamm Bowel Dis. 17(2) 573–582, [ISSN 1536-4844](https://doi.org/10.1002/ibd.21345), doi:10.1002/ibd.21345, PMID [20848527](https://pubmed.ncbi.nlm.nih.gov/20848527/)

Cordell B, McCathy J (2013) A Case Study of Gut Fermentation Syndrome (Auto-Brewery) with Saccharomyces cerevisiae as the Causative Organism. International Journal of Clinical Medicine, 4, 309-312 doi:10.4236/ijcm.2013.47054 Published Online July 2013 (<http://www.scirp.org/journal/ijcm>)  
<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=33912>

Hughes PA, Moretta M, Lim A et al. (2014) Immune derived opioidergic inhibition of viscerosensory afferents 4 is decreased in Irritable Bowel Syndrome patients. Brain, Behavior, and Immunity  
<http://www.ncbi.nlm.nih.gov/pubmed/25063707>

[Progatzy F, Sangha NJ, Yoshida N et al. \(2014\) Dietary cholesterol directly induces acute inflammasome-dependent intestinal inflammation. Nature Communications 5, Article number: 5864 doi:10.1038/ncomms6864 <http://www.nature.com/ncomms/2014/141223/ncomms6864/full/ncomms6864.html> <http://www.justsciencenews.com/dietary-cholesterol-directly-induces-acute-inflammasome-dependent-intestinal-inflammation/>](#)

Stoll ML et al. (2014) [Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis](#). Arth Res Ther 16, 486.

Costello ME et al. (2014) [Intestinal dysbiosis in ankylosing spondylitis](#). Arth Rheum DOI: 10.1002/art.38967.

Schweig S (2014) [The Lyme and Gut Connection The Role of Diet and Gastrointestinal Health in Treating Lyme Disease](#) [https://www.youtube.com/watch?v=gBTQBnG\\_Uno](https://www.youtube.com/watch?v=gBTQBnG_Uno)

Salvioli B, Pellegatta G, Malacarne M et al. (2015) [Autonomic nervous system dysregulation in irritable bowel syndrome. Neurogastroenterology & Motility](#). DOI: 10.1111/nmo.12512 <http://onlinelibrary.wiley.com/doi/10.1111/nmo.12512/abstract>

Perlmutter D (2015) [Belly and the Brain](#) <https://www.youtube.com/watch?v=ClcENEEqn3A>

Gomm W, von Holt K, Friederike Thomé F et al. (2016) [Association of Proton Pump Inhibitors With Risk of Dementia. A Pharmacoepidemiological Claims Data Analysis](#) ONLINE FIRST JAMA Neurol. Published online February 15, 2016. [Article abstract](#), [Editorial extract](#) <http://archneur.jamanetwork.com/article.aspx?articleid=2487379> <http://www.aahs.org/medstaff/wp-content/uploads/PPIAlzheimer2016.pdf>

Dejea ChM, Fathi P, Craig JM et al. (2018) [Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria](#). Science 359(6375), 592-597 DOI: 10.1126/science.aah3648 <http://science.sciencemag.org/content/359/6375/592>  
**« We identified patchy bacterial biofilms composed predominately of *Escherichia coli* and *Bacteroides fragilis*. ... These data suggest an unexpected link between early neoplasia of the colon and tumorigenic bacteria. »**

- ➔ **Yersinia enterocolitica** <http://www.kabilahsystems.de/yersiniaenterocolitica.pdf>
- ➔ **Mykobakterien, mycobacteria (MOTT, MTM)** [http://www.kabilahsystems.de/atypical\\_mycobacteria.pdf](http://www.kabilahsystems.de/atypical_mycobacteria.pdf)
- ➔ **Alzheimer, Demenz** <http://www.erlebnishaft.de/alzheimerspirochaetosis.pdf>
- ➔ **Herzkrankheit, heart disease** <http://www.xerlebnishaft.de/herzkrankheit.pdf>
- ➔ **Zahn-Mundpflege, dental and oral care** [http://www.xerlebnishaft.de/zahn\\_mundpflege.pdf](http://www.xerlebnishaft.de/zahn_mundpflege.pdf)
- ➔ **Probiotika, probiotics** <http://www.kabilahsystems.de/probiotika.pdf>
- ➔ **„Cavete – Diagnosen“ und chronische Infektionskrankheiten** <http://www.erlebnishaft.de/kommentalternativ.pdf>

[Bernt - Dieter Huismans](#), Letzte Revision Mai 2018 [www.Huismans.click](http://www.Huismans.click)  
Back to top: [http://www.xerlebnishaft.de/gastroent\\_borr.pdf](http://www.xerlebnishaft.de/gastroent_borr.pdf)

